μ-δ Opioid receptor functional interaction: Insight using receptor-G protein fusions

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 683-690

  Snook, Laelie A ^a,c   Milligan, Graeme ^b   Kieffer, Brigitte L ^a   Massotte, Dominique ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; DELTA OPIATE RECEPTOR; DELTORPHIN; DELTORPHIN II; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLARGINYLTHREONYLPENICILLAMINYLTHREONINAMIDE 2,7 DISULFIDE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); HETERODIMER; MU OPIATE RECEPTOR; PERTUSSIS TOXIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CELL STRAIN HEK293; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BINDING SITE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIGAND BINDING; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

ANALGESICS, OPIOID; BENZAMIDES; BINDING SITES; BINDING, COMPETITIVE; BLOTTING, WESTERN; CELL LINE; CELL MEMBRANE; CELLS, CULTURED; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; GTP-BINDING PROTEINS; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; IMMUNOPRECIPITATION; LIGANDS; OLIGOPEPTIDES; PEPTIDES; PIPERAZINES; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; RECOMBINANT FUSION PROTEINS;

EID: 33745934035     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.101220     Document Type: Article

References (34)

1. Befort K, Tabbara L, Kling D, Maigret B, and Kieffer BL (1996) Role of aromatic transmembrane residues of the δ-opioid receptor in ligand recognition. J Biol Chem 271:10161-10168.
2. Bodnar RJ and Hadjimarkou MM (2003) Endogenous opiates and behavior: 2002. Peptides 24:1241-1302.
3. Carrillo JJ, Pediani J, and Milligan G (2003) Dimers of class A G protein-coupled receptors function via agonist-mediated trans-activation of associated G proteins. J Biol Chem 278:42578-42587.
4. Chavkin C, McLaughlin JP, and Celver JP (2001) Regulation of opioid receptor function by chronic agonist exposure: constitutive activity and desensitization. Mol Pharmacol 60:20-25.
5. Chen C, Li J, Bot G, Szabo I, Rogers TJ, and Liu-Chen LY (2004) Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 483:175-186.
6. Costa T and Herz A (1989) Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325.
7. Dean MK, Higgs C, Smith RE, Bywater RP, Snell CR, Scott PD, Upton GJG, Howe TJ, and Reynolds CA (2001) Dimerization of G-protein-coupled receptors. J Med Chem 44:4595-4614.
8. Filizola M and Weinstein H (2002) Structural models for dimerization of G-protein coupled receptors: the opioid receptor homodimers. Biopolymers 66:317-325.
9. Fotiadis D, Liang Y, Filipek S, Saperstein DA, Engel A, and Palczewski K (2003) Atomic-force microscopy: rhodopsin dimers in native disc membranes. Nature (Lond) 421:127-128.
10. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, and O'Dowd BF (2000) Oligomerization of μ- and δ-opioid receptors. Generation of novel functional properties. J Biol Chem 275:26128-26135.
11. Gomes I, Gupta A, Filipovska J, Szeto HH, Pintar JE, and Devi LA (2004) A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia. Proc Natl Acad Sci USA 101:5135-5139.
12. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, and Devi LA (2000) Heterodimerization of mu and delta opioid receptors: a role in opiate synergy. J Neurosci 20:1-5.
13. Jordan BA and Devi LA (1999) G-protein-coupled receptor heterodimerization modulates receptor function. Nature (Lond) 399:697-700.
14. 2A-adrenergic receptors. Mol Pharmacol 64:1317-1324.
15. 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. Proc Natl Acad Sci USA 98:343-348.
16. Law PY, Erickson-Herbrandson LJ, Zha QQ, Solberg J, Chu J, Sarre A, and Loh HH (2005) Heterodimerization of μ- and δ-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem 280:11152-11164.
17. Liang Y, Fotiadis D, Filipek S, Saperstein DA, Palczewski K, and Engel A (2003) Organization of the G protein-coupled receptors rhodopsin and opsin in native membranes. J Biol Chem 278:21655-21662.
18. i2α fused to the human mu opioid receptor differently. J Neurochem 81:1372-1382.
19. Massotte D and Kieffer BL (1998) A molecular basis for opioid action, in Essays in Biochemistry: Molecular Biology of the Brain (Higgins SJ ed) pp 65-77, Portland Press, London, UK.
20. McVey M, Ramsay D, Kellett E, Rees S, Wilson S, Pope AJ, and Milligan G (2001) Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human δ-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. J Biol Chem 276:14092-14099.
21. Milligan G (2004) G protein-coupled receptor dimerization: function and ligand pharmacology. Mol Pharmacol 66:1-7.
22. Milligan G and Bouvier M (2005) Methods to monitor the quaternary structure of G protein-coupled receptors. FEBS J 272:2914-2925.
23. Molinari P, Ambrosio C, Riitano D, Sbraccia M, Gro MC, and Costa T (2003) Promiscuous coupling at receptor-Gα fusion proteins. The receptor of one covalent complex interacts with the α-subunit of another. J Biol Chem 278:15778-15788.
24. Moon H-E, Cavalli A, Bahia DS, Hoffmann M, Massotte D, and Milligan G (2001) The human δ opioid receptor activates Gi1α more efficiently than Go1α. J Neurochem 76:1805-1813.
25. Park PS, Filipek S, Wells JW, and Palczewski K (2004) Oligomerization of G protein-coupled receptors: past, present and future. Biochemistry 43:15643-15656.
26. Pfeiffer M, Kirscht S, Stumm R, Koch T, Wu D, Laugsch M, Schroder H, Hollt V, and Schulz S (2003) Heterodimerization of substance P and μ-opioid receptors regulates receptor trafficking and resensitization. J Biol Chem 278:51630-51637.
27. Pfeiffer M, Koch T, Schroeder H, Laugsch M, Hoellt V, and Schulz S (2002) Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization and desensitization. J Biol Chem 277:19762-19772.
28. Prinster SC, Hague C, and Hall RA (2005) Heterodimerization of G protein-coupled receptors: specificity and functional significance. Pharmacol Rev 57:289-298.
29. Salvadori S, Guerrini R, Balboni G, Bianchi C, Bryant SD, Cooper PS, and Lazarus LH (1999) Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest μ agonism or μ antagonism. J Med Chem 42:5010-5019.
30. Schiller PW, Weltrowska G, Berezowska I, Nguyen TM, Wilkes BC, Lemieux C, and Chung NN (1999) The TIPP opioid peptide family: development of μ antagonists, μ agonists and mixed μ agonist/δ antagonists. Biopolymers 51:411-425.
31. Schulz A, Grosse R, Schultz G, Gudermann T, and Schoneberg T (2000) Structural implication for receptor oligomerization from functional reconstitution studies of mutant V2 vasopressin receptors. J Biol Chem 275:2381-2389.
32. 2 as an antagonist of peptide and alkaloid μ-agonists in an antinociception assay. J Pharmacol Exp Ther 304:301-309.
33. Strange PG (2002) Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23:89-95.
34. Tryoen-Toth P, Decaillot FM, Filliol D, Befort K, Lazarus LH, Schiller PW, Schmidhammer H, and Kieffer BL (2005) Inverse agonism and neutral antagonism at wild-type and constitutively active mutant δ opioid receptors. J Pharmacol Exp Ther 313:410-421.